

Fyarro (sirolimus protein-bound particles for injectable suspension)



Pharmacy Coverage Policy

Effective Date: February 23, 2022

Revision Date: October 25, 2023

Review Date: October 18, 2023

Line of Business: Medicare, Commercial, Medicaid - South Carolina, Medicaid - Ohio

Policy Type: Prior Authorization

Page: 1 of 2

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

Products Affected

Fyarro intravenous suspension

Listed Indications

[Perivascular epithelioid cell tumor](#)

Perivascular epithelioid cell tumor

Does the member meet all of the following criteria?

Criteria #1	The member had diagnosis of locally advanced unresectable or metastatic perivascular epithelioid cell tumor
Criteria #2	Fyarro (sirolimus protein-bound particles for injectable suspension) will be administered as monotherapy

Does the member have any of the following exclusions? If yes, approval may not be appropriate.

NOTE: Experimental/Investigational Use – Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

Exclusion #1	Member has a history of severe hypersensitivity to sirolimus, other rapamycin derivatives, or albumin.
Exclusion #2	Member experiences disease progression on Fyarro (sirolimus protein-bound particles for injectable suspension)

Approval Duration

Initial	six month durations
---------	---------------------

[Back to top](#)

Background

This is a prior authorization policy about Fyarro (sirolimus protein-bound particles for injectable suspension).

Fyarro (sirolimus protein-bound particles for injectable suspension), mTOR inhibitor, is indicated for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Sirolimus protein-bound particles for injectable suspension is available as Fyarro in 100mg as single dose vials for reconstitution.

Provider Claim Codes

For medically billed requests, please visit www.humana.com/PAL. Select applicable Preauthorization and Notification List(s) for medical and procedural coding information.

Medical Terms

Fyarro; sirolimus protein-bound particles for injectable suspension; perivascular epithelioid cell tumor

References

Fyarro [prescribing information]. Aadi Bioscience, Inc. Pacific Palisades, CA. December 2021.

Fyarro (sirolimus protein-bound particles for injectable suspension)

Effective Date: 2/23/2022

Revision Date: 10/25/2023

Review Date: 10/18/2023

Line of Business: Medicare, Commercial, Medicaid - South Carolina, Medicaid - Ohio

Policy Type: Prior Authorization

Page: 2 of 2

Humana's documents are updated regularly online. When printed, the version of this document becomes uncontrolled. Do not rely on printed copies for the most up-to date version. Refer to http://apps.humana.com/tad/tad_new/home.aspx to verify that this is the current version before utilizing.

Disclaimer	State and federal law, as well as contract language, including definitions and specific inclusions/exclusions, take precedence over clinical policy and must be considered first in determining eligibility for coverage. Coverage may also differ for our Medicare and/or Medicaid members based on any applicable Centers for Medicare & Medicaid Services (CMS) coverage statements including National Coverage Determinations (NCD), Local Medical Review Policies (LMRP) and/or Local Coverage Determinations. See the CMS website at http://www.cms.hhs.gov/ . The member's health plan benefits in effect on the date services are rendered must be used. Clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Clinical technology is constantly evolving, and we reserve the right to review and update this policy periodically. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, electronic, mechanical, photocopying or otherwise without permission from Humana.
-------------------	--